143 related articles for article (PubMed ID: 28600397)
1. Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia.
Henrich A; Joerger M; Kraff S; Jaehde U; Huisinga W; Kloft C; Parra-Guillen ZP
J Pharmacol Exp Ther; 2017 Aug; 362(2):347-358. PubMed ID: 28600397
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.
Joerger M; Kraff S; Huitema AD; Feiss G; Moritz B; Schellens JH; Beijnen JH; Jaehde U
Clin Pharmacokinet; 2012 Sep; 51(9):607-17. PubMed ID: 22804749
[TBL] [Abstract][Full Text] [Related]
3. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
Hing J; Perez-Ruixo JJ; Stuyckens K; Soto-Matos A; Lopez-Lazaro L; Zannikos P
Clin Pharmacol Ther; 2008 Jan; 83(1):130-43. PubMed ID: 17597713
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel.
Fetterly GJ; Grasela TH; Sherman JW; Dul JL; Grahn A; Lecomte D; Fiedler-Kelly J; Damjanov N; Fishman M; Kane MP; Rubin EH; Tan AR
Clin Cancer Res; 2008 Sep; 14(18):5856-63. PubMed ID: 18794097
[TBL] [Abstract][Full Text] [Related]
5. Model-based neutrophil-guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information.
Wallin JE; Friberg LE; Karlsson MO
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):234-42. PubMed ID: 20050841
[TBL] [Abstract][Full Text] [Related]
6. Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?
Crombag MBS; Koolen SLW; Wijngaard S; Joerger M; Dorlo TPC; van Erp NP; Mathijssen RHJ; Beijnen JH; Huitema ADR
Pharm Res; 2019 Oct; 36(12):163. PubMed ID: 31617004
[TBL] [Abstract][Full Text] [Related]
7. A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy.
Latz JE; Karlsson MO; Rusthoven JJ; Ghosh A; Johnson RD
Cancer Chemother Pharmacol; 2006 Apr; 57(4):412-26. PubMed ID: 16322990
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.
Sun W; O'Dwyer PJ; Finn RS; Ruiz-Garcia A; Shapiro GI; Schwartz GK; DeMichele A; Wang D
J Clin Pharmacol; 2017 Sep; 57(9):1159-1173. PubMed ID: 28419480
[TBL] [Abstract][Full Text] [Related]
9. Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy.
Latz JE; Rusthoven JJ; Karlsson MO; Ghosh A; Johnson RD
Cancer Chemother Pharmacol; 2006 Apr; 57(4):427-35. PubMed ID: 16322992
[TBL] [Abstract][Full Text] [Related]
10. Mechanism-based pharmacokinetic model for paclitaxel.
Henningsson A; Karlsson MO; Viganò L; Gianni L; Verweij J; Sparreboom A
J Clin Oncol; 2001 Oct; 19(20):4065-73. PubMed ID: 11600609
[TBL] [Abstract][Full Text] [Related]
11. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
12. Semimechanistic cell-cycle type-based pharmacokinetic/pharmacodynamic model of chemotherapy-induced neutropenic effects of diflomotecan under different dosing schedules.
Mangas-Sanjuan V; Buil-Bruna N; Garrido MJ; Soto E; Trocóniz IF
J Pharmacol Exp Ther; 2015 Jul; 354(1):55-64. PubMed ID: 25948593
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs.
Kloft C; Wallin J; Henningsson A; Chatelut E; Karlsson MO
Clin Cancer Res; 2006 Sep; 12(18):5481-90. PubMed ID: 17000683
[TBL] [Abstract][Full Text] [Related]
14. A Bayesian population PK-PD model for ispinesib/docetaxel combination-induced myelosuppression.
Kathman SJ; Williams DH; Hodge JP; Dar M
Cancer Chemother Pharmacol; 2009 Feb; 63(3):469-76. PubMed ID: 18443793
[TBL] [Abstract][Full Text] [Related]
15. A Bayesian population PK-PD model of ispinesib-induced myelosuppression.
Kathman SJ; Williams DH; Hodge JP; Dar M
Clin Pharmacol Ther; 2007 Jan; 81(1):88-94. PubMed ID: 17186004
[TBL] [Abstract][Full Text] [Related]
16. Excel-Based Tool for Pharmacokinetically Guided Dose Adjustment of Paclitaxel.
Kraff S; Lindauer A; Joerger M; Salamone SJ; Jaehde U
Ther Drug Monit; 2015 Dec; 37(6):725-32. PubMed ID: 25774704
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for erythropenia in rats.
Kobuchi S; Ito Y; Hayakawa T; Nishimura A; Shibata N; Takada K; Sakaeda T
J Pharmacol Toxicol Methods; 2014; 70(2):134-44. PubMed ID: 25072509
[TBL] [Abstract][Full Text] [Related]
18. Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies.
Soto E; Keizer RJ; Trocóniz IF; Huitema AD; Beijnen JH; Schellens JH; Wanders J; Cendrós JM; Obach R; Peraire C; Friberg LE; Karlsson MO
Invest New Drugs; 2011 Oct; 29(5):984-95. PubMed ID: 20449627
[TBL] [Abstract][Full Text] [Related]
19. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of oxaliplatin for hematological toxicity in rats.
Kobuchi S; Katsuyama Y; Ito Y
Xenobiotica; 2020 Feb; 50(2):223-230. PubMed ID: 30938550
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.
Bruno R; Hille D; Riva A; Vivier N; ten Bokkel Huinnink WW; van Oosterom AT; Kaye SB; Verweij J; Fossella FV; Valero V; Rigas JR; Seidman AD; Chevallier B; Fumoleau P; Burris HA; Ravdin PM; Sheiner LB
J Clin Oncol; 1998 Jan; 16(1):187-96. PubMed ID: 9440742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
